H. Con. Res. 112, Establishing the budget for the US Government for FY 2013.
H.R. 5973/S. 2375, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2013.
H. J. Res. 117, Continuing Appropriations Resolution, 2013.
Medicare coverage and reimbursement.
H. Con. Res 112, Establishing the budget for the US Government for FY 2013.
H.R. 6684, Spending Reduction Act of 2012.
H.R. 8, American Taxpayer Relief Act of 2012.
Prescription Drug User Fee Act reauthorization.
Product exclusivity issues; pedigree issues.
Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation).
Pub. L. 111-152, Health Care and Education Reconciliation Act of 2010 (implementation).H.R. 5651, Food and Drug Administration Reform Act of 2012.
S. 2516, Food and Drug Administration Safety and Innnovation Act.
S. 3187, Food and Drug Administration Safety and Innovation Act.
S. 2292, Patients' FDA Act.
H.R. 6433, FDA User Fee Corrections Act of 2012.
340B-related issues.
Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation).
Pub. L. 111-152, Health Care and Education Reconciliation Act of 2010 (implementation).
Duration: January 1, 2008
to
December 31, 2012
General Issues: Budget/Appropriations , Medicare/Medicaid , Pharmacy , Health Issues , Copyright/Patent/Trademark , Financial Institutions/Investments/Securities , Medical/Disease Research/Clinical Labs
Spending: about $1,000,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2008: House of Representatives, U.S. Senate, U.S. Senate,, Health & Human Services - Dept of (HHS), Food & Drug Administration (FDA), Health Resources & Services Administration (HRSA), Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Anne Marie Polak
Leg. Correspondent for Rep. Mike Ferguson
Lauren Maddox
Asst. Sec'y / Comm. & Outreach, Dept. of Ed.
Comm. Director, H. Republican Conference
Deputy Press Secretary, Rep. Newt Gingrich
Press Secretary, Rep. Joel Hefley
Tom Sparkman
Health Policy Intern, Senate HELP Committee
Paul Brathwaite
Exec. Dir., Congressional Black Caucus
Executive Director Congressional Black Caucus
Oscar Ramirez
Special Assistant to the Secretary of Labor
Chief of Staff to Rep. Hilda Solis
Deputy Chief of Staff for Rep. Al Green
Legislative Director for Rep. Joe Baca
Andrew Kauders
Sr. Adv. Sen. Menendez; ED, House Demo Caucus
Senior Advisor, Sen. Bob Menendez
Executive Director, House Democratic Caucus
Donni Turner
Senior Staff Counsel, Sen. Max Cleland
Legislative Director, Rep. David Scott
Legislative Assistant, Senator Richard Durbin
Lantie Slenzak
Legislative Director, Rep. Gene Green
Sharon Cohen
n/a
Anthony Podesta
n/a
Elizabeth Morra
n/a
Seth Nichols
n/a
Jen Siciliano
n/a
DAN MATTOON
n/a
Gwen Mellor
n/a
Claudia James
n/a
MEREDITH BEATON
n/a
Thomas Sparkman
n/a
Donnice Turner
n/a
Daniele Baierlein
n/a
Randall Gerard
n/a
Nicole Young
n/a
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
4th Quarter, 2012
PODESTA GROUP, INC. terminated an engagement in which they represented MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY on Jan. 22, 2013.
Original Filing: 300542881.xml
Lobbying Issues
H. Con. Res. 112, Establishing the budget for the US Government for FY 2013.
H.R. 5973/S. 2375, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2013.
H. J. Res. 117, Continuing Appropriations Resolution, 2013.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Medicare coverage and reimbursement.
H. Con. Res 112, Establishing the budget for the US Government for FY 2013.
H.R. 6684, Spending Reduction Act of 2012.
H.R. 8, American Taxpayer Relief Act of 2012.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Prescription Drug User Fee Act reauthorization.
Product exclusivity issues; pedigree issues.
Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation).
Pub. L. 111-152, Health Care and Education Reconciliation Act of 2010 (implementation).H.R. 5651, Food and Drug Administration Reform Act of 2012.
S. 2516, Food and Drug Administration Safety and Innnovation Act.
S. 3187, Food and Drug Administration Safety and Innovation Act.
S. 2292, Patients' FDA Act.
H.R. 6433, FDA User Fee Corrections Act of 2012.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
340B-related issues.
Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation).
Pub. L. 111-152, Health Care and Education Reconciliation Act of 2010 (implementation).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2012
In Q3, PODESTA GROUP, INC. lobbied for MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY , earning $50,000. The report was filed on Oct. 22, 2012.
Original Filing: 300520839.xml
Lobbying Issues
H. Con. Res. 112, Establishing the budget for the US Government for FY 2013.
H.R. 5973/S. 2375, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2013.
H. J. Res. 117, Continuing Appropriations Resolution, 2013.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Medicare coverage and reimbursement.
H. Con. Res 112, Establishing the budget for the US Government for FY 2013.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Prescription Drug User Fee Act reauthorization.
Product exclusivity issues; pedigree issues.
Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation).
Pub. L. 111-152, Health Care and Education Reconciliation Act of 2010 (implementation).H.R. 5651, Food and Drug Administration Reform Act of 2012.
S. 2516, Food and Drug Administration Safety and Innnovation Act.
S. 3187, Food and Drug Administration Safety and Innovation Act.
S. 2292, Patients' FDA Act.
H.R. 6433, FDA User Fee Corrections Act of 2012.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
340B-related issues.
Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation).
Pub. L. 111-152, Health Care and Education Reconciliation Act of 2010 (implementation).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2012
In Q2, PODESTA GROUP, INC. lobbied for MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY , earning $50,000. The report was filed on July 20, 2012.
Original Filing: 300494956.xml
Lobbying Issues
FY 2013 budget resolutions.
H. Con. Res 112, Establishing the budget for the US Government for FY 2013.
H.R. 5973 / S. 2375, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2013.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Medicare coverage and reimbursement.
H. Con. Res 112, Establishing the budget for the US Government for FY 2013.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Prescription Drug User Fee Act reauthorization.
Product exclusivity issues; pedigree issues.
Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation).
Pub. L. 111-152, Health Care and Education Reconciliation Act of 2010 (implementation).H.R. 5651, Food and Drug Administration Reform Act of 2012.
S. 2516, Food and Drug Administration Safety and Innnovation Act.
S. 3187, Food and Drug Administration Safety and Innovation Act.
S. 2292, Patients' FDA Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
340B-related issues.
Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation).
Pub. L. 111-152, Health Care and Education Reconciliation Act of 2010 (implementation).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2012
In Q1, PODESTA GROUP, INC. lobbied for MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY , earning $50,000. The report was filed on April 19, 2012.
Original Filing: 300467672.xml
Lobbying Issues
FY 2013 budget resolutions.
H. Con. Res 112, Establishing the budget for the US Government for FY 2013.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Medicare coverage and reimbursement.
H. Con. Res 112, Establishing the budget for the US Government for FY 2013.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Prescription Drug User Fee Act reauthorization.
Product exclusivity issues; pedigree issues.
Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation).
Pub. L. 111-152, Health Care and Education Reconciliation Act of 2010 (implementation).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
340B-related issues.
Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation).
Pub. L. 111-152, Health Care and Education Reconciliation Act of 2010 (implementation).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2011
In Q4, PODESTA GROUP, INC. lobbied for MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY , earning $50,000. The report was filed on Jan. 20, 2012.
Original Filing: 300448210.xml
Lobbying Issues
FY 2012 budget resolutions.
H.R. 2055 and H.R. 3671, Consolidated Appropriations Act of 2011, Pub. L. 112-74.
H.J.RES. 95, Continuing Resolution through 12/23/11, Pub. L. 112-68.
H.J.RES. 94, Continuing Resolution through 12/17/11, Pub. L. 112-67.H.R. 2608, Continuing Appropriations Act, 2012, Pub. L. 122-36.
H.R. 3765, Temporary Payroll Tax Cut Continuation of 2011, Pub. L. 112-78.
H.R. 3630, Middle Class Tax Relief and Job Creation Act of 2011.
H.R. 3743, Middle Class Tax Relief and Job Creation Act of 2011.
H.R. 2112, Consolidated and Further Continuing Appropriations Act, 2012, Pub. L. 112-055.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Medicare coverage and reimbursement.
H.R. 2055 and H.R. 3671, Consolidated Appropriations Act of 2011, Pub. L. 112-74.
H.J.RES. 95, Continuing Resolution through 12/23/11, Pub. L. 112-68.
H.J.RES. 94, Continuing Resolution through 12/17/11, Pub. L. 112-67.H.R. 2608, Continuing Appropriations Act, 2012, Pub. L. 122-36.
H.R. 3765, Temporary Payroll Tax Cut Continuation of 2011, Pub. L. 112-78.
H.R. 3630, Middle Class Tax Relief and Job Creation Act of 2011.
H.R. 3743, Middle Class Tax Relief and Job Creation Act of 2011.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Prescription Drug User Fee Act reauthorization.
Product exclusivity issues.
S. 365 / Pub. L. 112-25, Budget Control Act of 2011.
H.R. 2112, Consolidated and Further Continuing Appropriations Act, 2012, Pub. L. 112-055.Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation).
Pub. L. 111-152, Health Care and Education Reconciliation Act of 2010 (implementation).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
340B-related issues.
H.R. 2055 and H.R. 3671, Consolidated Appropriations Act of 2011, Pub. L. 112-74.
H.J.RES. 95, Continuing Resolution through 12/23/11, Pub. L. 112-68.
H.J.RES. 94, Continuing Resolution through 12/17/11, Pub. L. 112-67.H.R. 2608, Continuing Appropriations Act, 2012, Pub. L. 122-36.
H.R. 3765, Temporary Payroll Tax Cut Continuation of 2011, Pub. L. 112-78.
H.R. 3630, Middle Class Tax Relief and Job Creation Act of 2011.
H.R. 3743, Middle Class Tax Relief and Job Creation Act of 2011.
H.R. 2674, 340B Program Improvement Act
Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation).
Pub. L. 111-152, Health Care and Education Reconciliation Act of 2010 (implementation).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2011
In Q3, PODESTA GROUP, INC. lobbied for MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY , earning $50,000. The report was filed on Oct. 20, 2011.
Original Filing: 300428301.xml
Lobbying Issues
FY 2012 budget resolutions.
H.R. 2017, Continuing Appropriations Act, 2012.
H.R. 2608, Continuing Appropriations Act, 2012.
S. 365 / Pub. L. 112-25, Budget Control Act of 2011.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Health & Human Services - Dept of (HHS) Health Resources & Services Administration (HRSA)
Lobbying Issues
H.R. 1249/S. 23, America Invents Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Medicare coverage and reimbursement.
Monitor debt ceiling negotiations.
H.R. 2017, Continuing Appropriations Act, 2012.
H.R. 2608, Continuing Appropriations Act, 2012.S. 365 / Pub. L. 112-25, Budget Control Act of 2011.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS)
Lobbying Issues
Prescription Drug User Fee Act reauthorization.
Product exclusivity issues.
S. 365 / Pub. L. 112-25, Budget Control Act of 2011.
H.R. 2112, Agriculture Appropriations.Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation).
Pub. L. 111-152, Health Care and Education Reconciliation Act of 2010 (implementation).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
340B-related issues.
H.R. 2017, Continuing Appropriations Act, 2012.
H.R. 2608, Continuing Appropriations Act, 2012.
S. 365 / Pub. L. 112-25, Budget Control Act of 2011.H.R. 2674, 340B Program Improvement Act
Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation).
Pub. L. 111-152, Health Care and Education Reconciliation Act of 2010 (implementation).
Agencies Lobbied
U.S. House of Representatives U.S. Senate Health & Human Services - Dept of (HHS) Health Resources & Services Administration (HRSA)
2nd Quarter, 2011
In Q2, PODESTA GROUP, INC. lobbied for MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY , earning $50,000. The report was filed on July 20, 2011.
Original Filing: 300403149.xml
Lobbying Issues
FY 2012 Budget resolutions.
H.R. 1473, Department of Defense and Full-Year Continuing Appropriations Act of 2011
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
H.R. 1249/S. 23, America Invents Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Medicare coverage and reimbursement.
Monitor debt ceiling negotiations, generally.
H.R. 1473, Department of Defense and Full-Year Continuing Appropriations Act of 2011
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Prescription Drug User Fee Act reauthorization.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Patient Protection and Affordable Care Act implementation.
340B-related issues.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
1st Quarter, 2011
In Q1, PODESTA GROUP, INC. lobbied for MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY , earning $50,000. The report was filed on April 20, 2011.
Original Filing: 300376207.xml
Lobbying Issues
FY 2012 Budget resolutions.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R. 1249/S. 23, America Invents Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Medicare coverage and reimbursement.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Prescription Drug User Fee Act reauthorization.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Patient Protection and Affordable Care Act implementation.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2010
In Q4, PODESTA GROUP, INC. lobbied for MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY , earning $50,000. The report was filed on Jan. 20, 2011.
Original Filing: 300354637.xml
Lobbying Issues
H.R. 3081 Continuing Appropriations Act, 2011 (340B Provisions)
S. 3686 Labor, Health and Human Services, and Education Appropriations Act, 2011
H.R. 3082, Continuing Appropriations and Surface Transportation Extensions Act, 2011; PL 111-322
H.J.RES.105, Making further continuing appropriations for fiscal year 2011, and for other purposes; PL 111-317H.J.RES.101, Making further continuing appropriations for fiscal year 2011, and for other purposes; PL 111-290
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
S. 515 Patent Reform Act of 2009
S. 610 Patent Reform Act of 2009
H.R. 1260 Patent Reform Act of 2009
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Medicare Issues
P.L. 111-148 Patient Protection and Affordable Care Act implementation
P.L. 111-152 Health Care and Education Reconciliation Act of 2010 implementation
H.R. 3081 Continuing Appropriations Act, 2011 (340B Provisions) H.R. 4899 Supplemental Appropriations Act, 2010 (AMP Revisions)
H.R. 5712 Veterans', Seniors', and Children's Health Technical Corrections Act of 2010 (340B Orphan Drug Childrens Hospital Provision)
S. 11 To restore the application of the 340B drug discount program to orphan drugs with respect to childrens hospitals
H.R. 3082, Continuing Appropriations and Surface Transportation Extensions Act, 2011; PL 111-322
H.J.RES.105, Making further continuing appropriations for fiscal year 2011, and for other purposes; PL 111-31
H.J.RES.101, Making further continuing appropriations for fiscal year 2011, and for other purposes; PL 111-290
H.R. 4994, Medicare and Medicaid Extenders Act of 2010; P.L. 111-309
H.R. 5712, The Physician Payment and Therapy Relief Act of 2010; P.L. 111-286
Agencies Lobbied
U.S. House of Representatives U.S. Senate,
Lobbying Issues
Drug Safety/Pedigree Bills
P.L. 111-148 Patient Protection and Affordable Care Act
P.L. 111-152 Health Care and Education Reconciliation Act of 2010
Agencies Lobbied
U.S. House of Representatives U.S. Senate,
Lobbying Issues
P.L. 111-148 Patient Protection and Affordable Care Act
P.L. 111-152 Health Care and Education Reconciliation Act of 2010
H.R. 3081 Continuing Appropriations Act, 2011 (340B Provisions)
H.R. 4994, Medicare and Medicaid Extenders Act of 2010; P.L. 111-309 H.R. 4899 Supplemental Appropriations Act, 2010 (AMP Revisions)
H.R. 5712 Veterans', Seniors', and Children's Health Technical Corrections Act of 2010 (340B Orphan Drug Childrens Hospital Provision)
S. 11 To restore the application of the 340B drug discount program to orphan drugs with respect to childrens hospitals
H.R. 5712, The Physician Payment and Therapy Relief Act of 2010; P.L. 111-286
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2010
In Q3, PODESTA GROUP, INC. lobbied for MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY , earning $50,000. The report was filed on Oct. 18, 2010.
Original Filing: 300316921.xml
Lobbying Issues
H.R. 3081 Continuing Appropriations Act, 2011 (340B Provisions)
S. 3686 Labor, Health and Human Services, and Education Appropriations Act, 2011
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
S. 515 Patent Reform Act of 2009
S. 610 Patent Reform Act of 2009
H.R. 1260 Patent Reform Act of 2009
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Medicare Issues
P.L. 111-148 Patient Protection and Affordable Care Act
P.L. 111-152 Health Care and Education Reconciliation Act of 2010
H.R. 3081 Continuing Appropriations Act, 2011 (340B Provisions) S. Amdt. (Baucus) to H.R. 4849 Small Business and Infrastructure Jobs Tax Act of 2010 (340B Provisions)
H.R. 1586 Education Jobs and Medicaid Funding Bill (AMP Revisions)
H.R. 4899 Supplemental Appropriations Act, 2010 (AMP Revisions)
H.R. 5712 Veterans', Seniors', and Children's Health Technical Corrections Act of 2010 (340B Orphan Drug Childrens Hospital Provision)
S. 11 To restore the application of the 340B drug discount program to orphan drugs with respect to childrens hospitals
Agencies Lobbied
U.S. House of Representatives U.S. Senate,
Lobbying Issues
Drug Safety/Pedigree Bills
P.L. 111-148 Patient Protection and Affordable Care Act
P.L. 111-152 Health Care and Education Reconciliation Act of 2010
Agencies Lobbied
U.S. House of Representatives U.S. Senate Health & Human Services - Dept of (HHS) Food & Drug Administration (FDA)
Lobbying Issues
P.L. 111-148 Patient Protection and Affordable Care Act
P.L. 111-152 Health Care and Education Reconciliation Act of 2010
H.R. 3081 Continuing Appropriations Act, 2011 (340B Provisions)
S. Amdt. (Baucus) to H.R. 4849 Small Business and Infrastructure Jobs Tax Act of 2010 (340B Provisions)H.R. 1586 Education Jobs and Medicaid Funding Bill (AMP Revisions)
H.R. 4899 Supplemental Appropriations Act, 2010 (AMP Revisions)
H.R. 5712 Veterans', Seniors', and Children's Health Technical Corrections Act of 2010 (340B Orphan Drug Childrens Hospital Provision)
S. 11 To restore the application of the 340B drug discount program to orphan drugs with respect to childrens hospitals
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2010
In Q2, PODESTA GROUP, INC. lobbied for MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY , earning $50,000. The report was filed on July 19, 2010.
Original Filing: 300293468.xml
Lobbying Issues
H.R. 4872 Health Care and Education Reconciliation Act of 2010
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
S. 515 Patent Reform Act of 2009
S. 610 Patent Reform Act of 2009
H.R. 1260 Patent Reform Act of 2009
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Medicare issues
H.R. 3590 Patient Protection and Affordable Care Act
H.R. 4872 Health Care and Education Reconciliation Act of 2010
H.R. 4213 American Jobs and Closing Loopholes Act of 2010H.R. 2847 Hiring Incentives to Restore Employment Act
H.R. 4851 Continuing Extension Act of 2010
H.R. 3962 Preservation of Access to Care for Medicare Beneficiaries and Pension Relief Act of 2010
Agencies Lobbied
U.S. House of Representatives U.S. Senate,
Lobbying Issues
S. 717 21st Century Cancer ALERT (Access to Life Saving Early detection, Research and Treatment) Act
H.R. 3590 Patient Protection and Affordable Care Act
H.R. 4872 Health Care and Education Reconciliation Act of 2010
Agencies Lobbied
U.S. House of Representatives U.S. Senate Health & Human Services - Dept of (HHS) Food & Drug Administration (FDA)
Lobbying Issues
H.R. 3590 Patient Protection and Affordable Care Act
H.R. 4872 Health Care and Education Reconciliation Act of 2010
H.R. 4213 Workers, State, and Business Relief Act of 2010
H.R. 2847 Hiring Incentives to Restore Employment ActH.R. 4851 Continuing Extension Act of 2010
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2010
In Q1, PODESTA GROUP, INC. lobbied for MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY , earning $50,000. The report was filed on April 20, 2010.
Original Filing: 300274692.xml
Lobbying Issues
H.R. 4872 Health Care and Education Reconciliation Act of 2010
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
S. 515 Patent Reform Act of 2009
S. 610 Patent Reform Act of 2009
H.R. 1260 Patent Reform Act of 2009
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Medicare issues
H.R. 3590 Patient Protection and Affordable Care Act
H.R. 4872 Health Care and Education Reconciliation Act of 2010
H.R. 4213 Workers, State, and Business Relief Act of 2010H.R. 2847 Hiring Incentives to Restore Employment Act
H.R. 4851 Continuing Extension Act of 2010
Agencies Lobbied
U.S. House of Representatives U.S. Senate,
Lobbying Issues
S. 717 21st Century Cancer ALERT (Access to Life Saving Early detection, Research and Treatment) Act
H.R. 3590 Patient Protection and Affordable Care Act
H.R. 4872 Health Care and Education Reconciliation Act of 2010
Agencies Lobbied
U.S. House of Representatives U.S. Senate Health & Human Services - Dept of (HHS) Food & Drug Administration (FDA)
Lobbying Issues
H.R. 3590 Patient Protection and Affordable Care Act
H.R. 4872 Health Care and Education Reconciliation Act of 2010
H.R. 4213 Workers, State, and Business Relief Act of 2010
H.R. 2847 Hiring Incentives to Restore Employment ActH.R. 4851 Continuing Extension Act of 2010
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2009
In Q4, PODESTA GROUP, INC. lobbied for MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY , earning $50,000. The report was filed on Jan. 19, 2010.
Original Filing: 300239825.xml
Lobbying Issues
Comparative Effectiveness
H.R. 1 American Recovery and Reinvestment Act of 2009
S. Con. Res. 13
H. Con. Res. 85H.R. 3288 Consolidated Appropriations Act, 2010, LHHS - Division D
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
S. 515 Patent Reform Act of 2009
S. 610 Patent Reform Act of 2009
H.R. 1260 Patent Reform Act of 2009
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Medicare issues
S. 301 Physician Payments Sunshine Act of 2009
S. 717 21st Century Cancer ALERT (Access to Life Saving Early detection, Research and Treatment) Act
S. 1679 Affordable Health Choices Act H.R. 3200 American Health Choices Act of 2009
Tri Caucus Healthcare Reform Bill
S. 1796 Americas Healthy Future Act of 2009
S. 1110 Medicare Payment Advisory Commission (MedPAC) Reform Act of 2009
H.R. 2502 Comparative Effectiveness Research Act of 2009
S. 1213 Patient-Centered Outcomes Research Act of 2009
H.R. 3962 Affordable Health Care for America Act
H.R. 3590 Patient Protection and Affordable Care Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate,
Lobbying Issues
H.R. 1427 Promoting Innovation and Access to Life-Saving Medicine
H.R. 1548 Pathway for Biosimilars Act
S. 726 Promoting Innovation and Access to Life-Saving Medicine Act
S. 717 21st Century Cancer ALERT (Access to Life Saving Early detection, Research and Treatment) Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate Health & Human Services - Dept of (HHS) Food & Drug Administration (FDA)
Lobbying Issues
S. 1679 Affordable Health Choices Act
H.R. 3200 American Health Choices Act of 2009
Tri Caucus Healthcare Reform Bill
S. 1796 Americas Healthy Future Act of 2009 S. 1110 Medicare Payment Advisory Commission (MedPAC) Reform Act of 2009
H.R. 2502 Comparative Effectiveness Research Act of 2009
S. 1213 Patient-Centered Outcomes Research Act of 2009
S. 301 Physician Payments Sunshine Act of 2009
H.R. 3962 Affordable Health Care for America Act
H.R. 3590 Patient Protection and Affordable Care Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2009
In Q3, PODESTA GROUP, INC. lobbied for MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY , earning $50,000. The report was filed on Oct. 20, 2009.
Original Filing: 300216754.xml
Lobbying Issues
Comparative Effectiveness
H.R. 1 American Recovery and Reinvestment Act of 2009
S. Con. Res. 13
H. Con. Res. 85
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
S. 515 Patent Reform Act of 2009
S. 610 Patent Reform Act of 2009
H.R. 1260 Patent Reform Act of 2009
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Medicare issues
S. 301 Physician Payments Sunshine Act of 2009
S. 717 21st Century Cancer ALERT (Access to Life Saving Early detection, Research and Treatment) Act
Kennedy American Health Choices Act of 2009H.R. 3200 American Health Choices Act of 2009
Tri Caucus Healthcare Reform Bill
Baucus/Finance Healthcare Reform Bill - America's Healthy Future Act of 2009
S. 1110 Medicare Payment Advisory Commission (MedPAC) Reform Act of 2009
H.R. 2502 Comparative Effectiveness Research Act of 2009
S. 1213 Patient-Centered Outcomes Research Act of 2009
Agencies Lobbied
U.S. House of Representatives U.S. Senate,
Lobbying Issues
H.R. 1427 Promoting Innovation and Access to Life-Saving Medicine
H.R. 1548 Pathway for Biosimilars Act
S. 726 Promoting Innovation and Access to Life-Saving Medicine Act
S. 717 21st Century Cancer ALERT (Access to Life Saving Early detection, Research and Treatment) Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate Health & Human Services - Dept of (HHS) Food & Drug Administration (FDA)
Lobbying Issues
Kennedy American Health Choices Act of 2009
H.R. 3200 American Health Choices Act of 2009
Tri Caucus Healthcare Reform Bill
Baucus/Finance Healthcare Reform Bill - America's Healthy Future Act of 2009S. 1110 Medicare Payment Advisory Commission (MedPAC) Reform Act of 2009
H.R. 2502 Comparative Effectiveness Research Act of 2009
S. 1213 Patient-Centered Outcomes Research Act of 2009
S. 301 Physician Payments Sunshine Act of 2009
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2009
PODESTA GROUP, INC. amended a lobbying report for representation of MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY in Q22009 on Oct. 26, 2011.
Original Filing: 300430956.xml
Lobbying Issues
Comparative Effectiveness
H.R. 1 American Recovery and Reinvestment Act of 2009
S. Con. Res. 13
H. Con. Res. 85
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
S. 515 Patent Reform Act of 2009
S. 610 Patent Reform Act of 2009
H.R. 1260 Patent Reform Act of 2009
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Medicare issues
S. 301 Physician Payments Sunshine Act of 2009
S. 717 21st Century Cancer ALERT (Access to Life Saving Early detection, Research and Treatment) Act
Kennedy Healthcare Reform BillHouse Tri Committee Healthcare Reform Bill
Tri Caucus Healthcare Reform Bill
Senate Finance Healthcare Reform Bill
S. 1110 Medicare Payment Advisory Commission (MedPAC) Reform Act of 2009
H.R. 2502 Comparative Effectiveness Research Act of 2009
S. 1213 Patient-Centered Outcomes Research Act of 2009
Agencies Lobbied
U.S. House of Representatives U.S. Senate,
Lobbying Issues
H.R. 1427 Promoting Innovation and Access to Life-Saving Medicine
H.R. 1548 Pathway for Biosimilars Act
S. 726 Promoting Innovation and Access to Life-Saving Medicine Act
S. 717 21st Century Cancer ALERT (Access to Life Saving Early detection, Research and Treatment) Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate Health & Human Services - Dept of (HHS) Food & Drug Administration (FDA)
Lobbying Issues
Kennedy Healthcare Reform Bill
House Tri Committee Healthcare Reform Bill
Tri Caucus Healthcare Reform Bill
Senate Finance Healthcare Reform BillS. 1110 Medicare Payment Advisory Commission (MedPAC) Reform Act of 2009
H.R. 2502 Comparative Effectiveness Research Act of 2009
S. 1213 Patient-Centered Outcomes Research Act of 2009
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2009
In Q2, PODESTA GROUP, INC. lobbied for MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY , earning $50,000. The report was filed on July 17, 2009.
Original Filing: 300183841.xml
Lobbying Issues
Comparative Effectiveness
H.R. 1 American Recovery and Reinvestment Act of 2009
S. Con. Res. 13
H. Con. Res. 85
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
S. 515 Patent Reform Act of 2009
S. 610 Patent Reform Act of 2009
H.R. 1260 Patent Reform Act of 2009
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Medicare issues
S. 301 Physician Payments Sunshine Act of 2009
S. 717 21st Century Cancer ALERT (Access to Life Saving Early detection, Research and Treatment) Act
Kennedy Healthcare Reform BillHouse Tri Committee Healthcare Reform Bill
Tri Caucus Healthcare Reform Bill
Senate Finance Healthcare Reform Bill
S. 1110 Medicare Payment Advisory Commission (MedPAC) Reform Act of 2009
H.R. 2502 Comparative Effectiveness Research Act of 2009
S. 1213 Patient-Centered Outcomes Research Act of 2009
Agencies Lobbied
U.S. House of Representatives U.S. Senate,
Lobbying Issues
H.R. 1427 Promoting Innovation and Access to Life-Saving Medicine
H.R. 1548 Pathway for Biosimilars Act
S. 726 Promoting Innovation and Access to Life-Saving Medicine Act
S. 717 21st Century Cancer ALERT (Access to Life Saving Early detection, Research and Treatment) Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate Health & Human Services - Dept of (HHS) Food & Drug Administration (FDA)
Lobbying Issues
Kennedy Healthcare Reform Bill
House Tri Committee Healthcare Reform Bill
Tri Caucus Healthcare Reform Bill
Senate Finance Healthcare Reform BillS. 1110 Medicare Payment Advisory Commission (MedPAC) Reform Act of 2009
H.R. 2502 Comparative Effectiveness Research Act of 2009
S. 1213 Patient-Centered Outcomes Research Act of 2009
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2009
In Q1, PODESTA GROUP, INC. lobbied for MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY , earning $50,000. The report was filed on April 19, 2009.
Original Filing: 300155873.xml
Lobbying Issues
Comparative Effectiveness
H.R. 1 American Recovery and Reinvestment Act of 2009
S. Con. Res. 13
H. Con. Res. 85
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R. 574 Medicare Home Infusion Therapy Coverage Act of 2009
S. 254 Medicare Home Infusion Therapy Coverage Act of 2009
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Medicare issues
S. 301 Physician Payments Sunshine Act of 2009
Agencies Lobbied
U.S. House of Representatives U.S. Senate,
Lobbying Issues
H.R. 1427 Promoting Innovation and Access to Life-Saving Medicine
H.R. 1548 Pathway for Biosimilars Act
S. 726 Promoting Innovation and Access to Life-Saving Medicine Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate Health & Human Services - Dept of (HHS) Food & Drug Administration (FDA)
4th Quarter, 2008
In Q4, PODESTA GROUP, INC. lobbied for MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY , earning $50,000. The report was filed on Jan. 21, 2009.
Original Filing: 300128604.xml
Lobbying Issues
House Concurrent Resolution 312 FY09 Budget Resolution
Senate Concurrent Resolution 70 FY09 Budget Resolution
Drug Importation
Comparative EffectivenessLHHS Appropriations - drug importation issues
Homeland Appropriations - drug importation issues
Agriculture Appropriations - drug importation issues
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
S. 1145, Patent Reform Act of 2007, entire bill
S. 3600, Patent Reform Act of 2008, entire bill
H R. 1908, Patent Reform Act of 2007, entire bill
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
H. R. 3162, Children's Health and Medicare Protection Act of 2007
H. R. 5480, Medicare Funding Warning Response Act of 2008
S. 2029, Physician Payments Sunshine Act of 2007S. 2662, Medicare Funding Warning Response Act of 2008
S. 3, Medicare Prescription Drug Price Negotiation Act, Medicare noninterference provisions
2008 Medicare Bill
Comparative Effectiveness
H.R. 1424, Emergency Economic Stabilization Act of 2008
Agencies Lobbied
U.S. House of Representatives U.S. Senate Executive Office of the President (EOP) Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS)
Lobbying Issues
H. R. 1038, Access to Life-Saving Medicine Act, follow-on biologics
H. R. 1956, Patient Protection and Innovative Biologic Medicines Act of 2007, follow-on biologics
H. R. 5629, Pathway for Biosimilars Act
S. 1505, Affordable Biologics for Consumers Act of 2007, follow-on biologics
S. 1695, Biologics Price Competition and Innovation Act of 2007, follow-on biologics
S. 2029, Physician Payments Sunshine Act of 2007
S. 623, Access to Life-Saving Medicine Act, follow-on biologics
Agencies Lobbied
U.S. House of Representatives U.S. Senate Health & Human Services - Dept of (HHS) Food & Drug Administration (FDA)
3rd Quarter, 2008
In Q3, PODESTA GROUP, INC. lobbied for MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY , earning $50,000. The report was filed on Oct. 17, 2008.
Original Filing: 300099888.xml
Lobbying Issues
House Concurrent Resolution 312 FY09 Budget Resolution
Senate Concurrent Resolution 70 FY09 Budget Resolution
Drug Importation
Comparative EffectivenessLHHS Appropriations - drug importation issues
Homeland Appropriations - drug importation issues
Agriculture Appropriations - drug importation issues
H.R. 2638, Consolidated Security, Disaster Assistance, and Continuing Appropriations Act, 2009
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
S. 1145, Patent Reform Act of 2007, entire bill
S. 3600, Patent Reform Act of 2008
H R. 1908, Patent Reform Act of 2007, entire bill
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
H. R. 3162, Children's Health and Medicare Protection Act of 2007
H. 4, Medicare Prescription Drug Price Negotiation Act, Medicare noninterference provisions
H. R. 5480, Medicare Funding Warning Response Act of 2008
S. 2029, Physician Payments Sunshine Act of 2007S. 2662, Medicare Funding Warning Response Act of 2008
S. 3, Medicare Prescription Drug Price Negotiation Act, Medicare noninterference provisions
2008 Medicare Bill
Comparative Effectiveness
H.R. 6331, Medicare Improvements for Patients and Providers Act of 2008
H.R. 1424, Emergency Economic Stabilization Act of 2008
S. 3101, Medicare Improvements for Patients and Providers Act of 2008
Agencies Lobbied
U.S. House of Representatives U.S. Senate Executive Office of the President (EOP) Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS)
Lobbying Issues
H. R. 1038, Access to Life-Saving Medicine Act, follow-on biologics
H. R. 1956, Patient Protection and Innovative Biologic Medicines Act of 2007, follow-on biologics
H. R. 5629, Pathway for Biosimilars Act
S. 1505, Affordable Biologics for Consumers Act of 2007, follow-on biologics
S. 1695, Biologics Price Competition and Innovation Act of 2007, follow-on biologics
S. 2029, Physician Payments Sunshine Act of 2007
S. 623, Access to Life-Saving Medicine Act, follow-on biologics
Agencies Lobbied
U.S. House of Representatives U.S. Senate Health & Human Services - Dept of (HHS) Food & Drug Administration (FDA)
2nd Quarter, 2008
In Q2, PODESTA GROUP, INC. lobbied for MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY , earning $50,000. The report was filed on July 21, 2008.
Original Filing: 300082565.xml
Lobbying Issues
House Concurrent Resolution 312 FY09 Budget Resolution
Senate Concurrent Resolution 70 FY09 Budget Resolution
Drug Importation
Comparative EffectivenessLHHS Appropriations - drug importation issues
Homeland Appropriations - drug importation issues
Agriculture Appropriations - drug importation issues
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
S. 1145, Patent Reform Act of 2007, entire bill
H R. 1908, Patent Reform Act of 2007, entire bill
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
H. R. 3162, Children's Health and Medicare Protection Act of 2007
H. 4, Medicare Prescription Drug Price Negotiation Act, Medicare noninterference provisions
H. R. 5480, Medicare Funding Warning Response Act of 2008
S. 2029, Physician Payments Sunshine Act of 2007S. 2662, Medicare Funding Warning Response Act of 2008
S. 3, Medicare Prescription Drug Price Negotiation Act, Medicare noninterference provisions
2008 Medicare Bill
Comparative Effectiveness
H.R. 6331, Medicare Improvements for Patients and Providers Act of 2008
S. 3101, Medicare Improvements for Patients and Providers Act of 2008
Agencies Lobbied
U.S. House of Representatives U.S. Senate Executive Office of the President (EOP) Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS)
Lobbying Issues
H. R. 1038, Access to Life-Saving Medicine Act, follow-on biologics
H. R. 1956, Patient Protection and Innovative Biologic Medicines Act of 2007, follow-on biologics
H. R. 5629, Pathway for Biosimilars Act
S. 1505, Affordable Biologics for Consumers Act of 2007, follow-on biologics
S. 1695, Biologics Price Competition and Innovation Act of 2007, follow-on biologics
S. 2029, Physician Payments Sunshine Act of 2007
S. 623, Access to Life-Saving Medicine Act, follow-on biologics
Agencies Lobbied
U.S. House of Representatives U.S. Senate Health & Human Services - Dept of (HHS) Food & Drug Administration (FDA)
1st Quarter, 2008
In Q1, PODESTA GROUP, INC. lobbied for MILLENNIUM PHARMACEUTICALS, INC , earning $50,000. The report was filed on April 21, 2008.
Original Filing: 300055870.xml
Lobbying Issues
House Concurrent Resolution 312 FY09 Budget Resolution
Senate Concurrent Resolution 70 FY09 Budget Resolution
Drug Importation
Comparative EffectivenessLHHS Appropriations
Homeland Appropriations
Agriculture Appropriations
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
S. 1145, Patent Reform Act of 2007, entire bill
H R. 1908, Patent Reform Act of 2007, entire bill
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
H. R. 3162, Children's Health and Medicare Protection Act of 2007
H. 4, Medicare Prescription Drug Price Negotiation Act, Medicare noninterference provisions
H. R. 5480, Medicare Funding Warning Response Act of 2008
S. 2029, Physician Payments Sunshine Act of 2007S. 2662, Medicare Funding Warning Response Act of 2008
S. 3, Medicare Prescription Drug Price Negotiation Act, Medicare noninterference provisions
2008 Medicare Bill
Comparative Effectiveness
Agencies Lobbied
U.S. House of Representatives U.S. Senate Executive Office of the President (EOP) Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS)
Lobbying Issues
H. R. 1038, Access to Life-Saving Medicine Act, follow-on biologics
H. R. 1956, Patient Protection and Innovative Biologic Medicines Act of 2007, follow-on biologics
H. R. 5629, Pathway for Biosimilars Act
S. 1505, Affordable Biologics for Consumers Act of 2007, follow-on biologics
S. 1695, Biologics Price Competition and Innovation Act of 2007, follow-on biologics
S. 2029, Physician Payments Sunshine Act of 2007
S. 623, Access to Life-Saving Medicine Act, follow-on biologics
Agencies Lobbied
U.S. House of Representatives U.S. Senate Health & Human Services - Dept of (HHS) Food & Drug Administration (FDA)
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate